公司销售利卡灵-B 51020-87-2图片中药标准品,还同时销售CP(中检所产品指定代理商)英国实验室LGC 医药杂质标准品、 加拿大TRC标准品 、EP(欧洲药典) 、USP(美国药典)、BP(英国药典) 、(WHO)世界卫生组织药物标准品 、NIST 、 美国Accustandard标准品,美国ChemService标准品等各种产品。种类齐全,到货迅速。更多详细信息欢迎您来电咨询!
产品中文名称: 利卡灵-B 51020-87-2图片
英文名: (-)-Licarin B
英文别名: 1,3-Benzodioxole, 5-[(2R,3R)-2,3-dihydro-7-methoxy-3-methyl-5-(1E)-1-propenyl-2-benzofuranyl]- (9CI)
CAS登录号: 51020-87-2
分子式: C20H20O4
分子量: 324.38
利卡灵-B 51020-87-2图片分子结构:
外观: 白色结晶(石油醚-丙酮)
规格: 20mg/支
纯度: ≥ 98%
用途: 用于含量测定/鉴定/药理实验等。
提取来源: 肉豆蔻(Myristica fragrans Houtt)干燥成熟种仁
熔点: 89-90℃(石油醚-乙酸乙酯)
旋光度: -45.4°(***)
药理药效: 现代药理学研究表明,肉豆蔻具有KJ、XY、镇静、抗肿瘤等作用。
贮存条件: 4℃冷藏、密封、避光
有效期: 2年
产品名称 | 利卡灵-B 51020-87-2图片
|
英文名称 | (-)-Licarin B
|
包装 | 可根据客户要求订制 |
注意事项:
利卡灵-B 51020-87-2图片纯度高,检测/鉴别精确,稳定性强,为了防止产品含量降低,不宜暴露在空气中,应防潮、避光和抗氧化包装,保存应以提高物质稳定性为原则,尽可能在干燥、低温条件下储藏(液体或易潮解物质分装在熔封的玻璃安瓶内)。
规格:规格包装齐全可根据要求定制包装。
用途:产品供科研实验使用,详情可参照产品说明书。
运输:快递免费送货上门,全国各地现货供应。
不能直接用于人体,出库的产品全部经过严格的检测,保证质量。标准品/对照品一般用于鉴别、检查和含量 (或效价)测定。对于鉴别来说,只要确认未混淆标准物质 即可,而检查和含量测定则不同,大部分检查项目和含量测定项目均有明确的标准。这就要求在进行检验时要控制实验误差,在进行标准物质称量时未严格按照药典等标准要求进行。
1号染色体开放阅读框127抗体 规格: ?0.2ml 英文名称: C1orf127
1号染色体开放阅读框129抗体 规格: ?0.2ml 英文名称: C1orf129
1号染色体开放阅读框130抗体 规格: ?0.2ml 英文名称: C1orf130
1号染色体开放阅读框131抗体 规格: ?0.2ml 英文名称: C1orf131
1号染色体开放阅读框135抗体 规格: ?0.2ml 英文名称: C1orf135
1号染色体开放阅读框141抗体 规格: ?0.2ml 英文名称: C1orf141
1号染色体开放阅读框144抗体 规格: ?0.2ml 英文名称: C1orf144
COPA蛋白抗体 规格: ?0.2ml 英文名称: alpha COP I
1号染色体开放阅读框185抗体 规格: ?0.2ml 英文名称: C1orf185
磷酸化热休克蛋白β5/α晶状体球蛋白B/αB-crystallin抗体 规格: ?0.1ml 英文名称: phospho-alpha B Crystallin (Ser19)
磷酸化α晶状体球蛋白B/αB-crystallin抗体 规格: ?0.1ml 英文名称: phospho-alpha B Crystallin (Ser45)
磷酸化热休克蛋白β5/α晶状体球蛋白B/αB-crystallin抗体 规格: ?0.1ml 英文名称: phospho-alpha B Crystallin (Ser53)
1号染色体开放阅读框167抗体 规格: ?0.2ml 英文名称: C1orf167
chondroitin sulfate E in the repeated disaccharide region.
Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members. Phosphorylation on Tyr-757 is required for SHC binding. Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin.
Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides.
Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP).
Beta-amyloid peptides are degraded by IDE.
DISEASE : Defects in APP are the cause of Alzheimer disease type 1 (AD1) [MIM:104300]. AD1 is a familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is 利卡灵-B 51020-87-2图片the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death.
Defects in APP are the cause of amyloidosis